Metastatic Colorectal Cancers Recruiting Phase 3 Trials for Cetuximab (DB00002)

Also known as: Colorectal Cancer Metastatic / Metastatic Colorectal Cancer / Metastatic Colorectal Cancer (MCRC) / Cancer - Metastatic Colorectal / Colorectal Cancer, Metastatic

DBCOND0063579 (Metastatic Colorectal Cancers)Recruiting3 IdentifierTitlePurposeDrugs
NCT04008030A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Patients With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)Treatment
NCT03803553Identification and Treatment Of Micrometastatic Disease in Stage III Colon CancerTreatment
NCT03391934A Clinical Trial to Determine the Therapeutic Efficacy and Safety Between Cetuximab® (Produced by CinnaGen) and FOLFIRI Compared With Erbitux® (Cetuximab, Produced by Merck Company) and FOLFIRI for RAS Wild-type Metastatic Colorectal Cancer PatientsTreatment
NCT03206151CMAB009 Combined With FOLFIRI First-line Treatment in Patients With RAS/BRAF Wild-type, Metastatic Colorectal CancerTreatment
NCT02934529Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus CetuximabTreatment
NCT01910610Multi-Line Therapy Trial in Unresectable Metastatic Colorectal CancerTreatment